Method and device for controlling mammalian reproductive cycle

• US 5,941,844 A
• Filed: 11/17/1997
• Issued: 08/24/1999
• Est. Priority Date: 11/17/1997
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Eckenhoff, deceased, James B.
• Primary Examiner(s): MENDEZ, MANUEL A
• Application Number:
  US08/972,029
• Time in Patent Office: 645 Days
• Field of Search: 604/49, 604/890.1, 604/20, 604/289, 607/115, 210/502.1, 210/638, 424/449
• US Class Current: 604/20
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

A method encompasses the substantially continuous electrotransport delivery of luteinizing hormone releasing hormone (LHRH), prologues, analogues, salts or mixtures thereof, preferably at a substantially constant rate, to a female mammal for the purpose of modifying its reproductive cycle. An electrotransport device substantially is suited for the continuous delivery of LHRH prologues, analogues, salts or mixtures thereof over an extended period of time to a mammal. The present technology may be successfully applied to the controlled breeding of mammals, such as thoroughbred race horses.

Claims

1. A method of inducing ovulation in a female mammal having seasonal estrous and anestrous periods, comprising administering an agent selected from the group consisting of LHRH, prodrugs of LHRH, analogs of LHRH, salts thereof and mixtures thereof, to the mammal during a seasonal anestrous period by electrotransport through a body surface of the mammal over a period of time effective to, and in an amount sufficient to, induce ovulation in the mammal.

2. The method of claim 1, including inseminating the mammal after inducing ovulation.

3. The method of claim 1, wherein the agent is continuously delivered by electrotransport for at least about 80% of the administration period.

4. The method of claim 3, wherein the predetermined time is about 3 to 7 days after initiating the electrotransport administration of the agent.

7. The method of claim 1, wherein the agent is delivered at a rate of about 0.1 to 10 mg over a period of about 1 to 10 days.

8. The method of claim 7, wherein the agent is delivered at a rate of about 0.5 to 5 mg.

9. The method of claim 1, wherein the agent is continuously delivered at a rate of about 0.05 to 15 μ

g/hr.

10. The method of claim 9, wherein the agent is continuously delivered at a rate of about 0.5 to 10 μ

g/hr.

11. The method of claim 1, wherein the body surface comprises skin of the mammal.

12. The method of claim 11, including shaving the skin of the mammal before administering the LHRH.

13. The method of claim 11, wherein the skin is a skin site selected from the group consisting of an area of the underside of the mammal, the underside of the mammal between the front legs, an interior surface of a leg, and the neck of the mammal.

14. The method of claim 1, wherein the agent is administered to a mammal located in the northern hemisphere between about January 1 and March 1.

15. The method of claim 1, wherein the LHRH is delivered at a substantially constant rate during the period of time.

16. The method of claim 1, including delivering a permeation enhancer to the body surface.

17. The method of claim 1, wherein the female mammal is a mare.

19. The method of claim 1, wherein the mammal is a mare and the insemination is with sperm from a thoroughbred horse.

5. A method of inducing ovulation in a female mammal having seasonal estrous and anestrous periods, comprising administering an agent selected from the group consisting of LHRH, prodrugs of LHRH, analogs of LHRH, salts thereof and mixtures thereof, to the mammal during a seasonal estrous period by electrotransport through a body surface of the mammal over a period of time effective to, and in an amount sufficient to, restart the estrous cycle of the mammal.

6. The method of claim 5, including inseminating the mammal after inducing ovulation.

18. The method of claim 5, wherein the female mammal is a mare, and the administration of the agent is initiated between about January 1 and March 1.